
Gilead Sciences names John Milligan new CEO
pharmafile | January 29, 2016 | Appointment | Medical Communications, Sales and Marketing | Gilead Sciences, John Martin, John Milligan
Gilead Sciences has announced that chairman and chief executive John Martin is to step down after 20 years at the helm, and will be replaced by current president and chief operating officer John Milligan.
The company said Martin would assume a new role as executive chairman, after more than a quarter of a century at Gilead.
Martin joined the company in 1990, and was made chief executive in 1996 and chairman of the board in 2008. His successor Milligan also joined Gilead in 1990 as a research scientist and was appointed chief operating officer in 2007 and president in 2008.
John Cogan, Gilead’s Lead Independent Director, comments: “John Martin has led Gilead as CEO for the past 20 years, and under his stewardship, the company has developed and delivered therapeutic advancements to millions of people around the world. His legacy is clear – and the vision he has set will continue with his contributions as executive chairman.”
John Martin praised his successor, saying: “Over the past 25 years, John Milligan has distinguished himself as an exceptional leader, serving in diverse management roles and overseeing multiple phases of growth and expansion into new therapeutic areas and geographies. The board of directors and I are confident in his ability to lead Gilead into the future.”
Joel Levy
Related Content

Gilead Foundation awards $6.5m in grants to support STEM education
Gilead Sciences has committed over $6.5m in grant funding towards improving science, technology, engineering and …

Gilead’s Veklury recommended by NICE for COVID-19 treatment
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …

Gilead and Merck share data from phase 2 trial of HIV treatment
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …






